KMO

Across TCGA pan-cancer cohorts, KMO mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated KMO data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher KMO mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated KMO expression acts as an unfavorable survival marker.

CCRCC, LUAD, and GBM are the cancer types where KMO mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.612	1.000	.001	22	view →
LUAD	OS	Median	II,III,IV	0.293	0.837	<.001	7	view →
GBM	OS	Tertile	All	0.726	0.928	.031	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

KMO–CCRCC (OS)

Open the CCRCC breakdown →